Curasight (CURAS) Q4 2024 earnings summary

Executive summary

• Advanced clinical development of uTREATⓇ, selecting brain cancer (high-grade glioma) as the first indication, with first patient dosing planned for mid-2025.

• Entered a global radioisotope supply agreement with Curium for Lutetium-177, supporting uTREATⓇ development.

• Progressed phase II trial of UTRACEⓇ in prostate cancer, with ongoing partnership with Curium and milestone payments received.

• Rights issue in Q4 2024 was heavily oversubscribed, and warrant exercises provided additional capital.

• Focused on business development, strategic partnerships, and financial planning to support clinical ambitions.

Financial highlights

• Q4 2024 gross loss: kDKK -10,210 (Q4 2023: kDKK -5,493); operating loss: kDKK -11,721 (Q4 2023: kDKK -7,354); loss for the period: kDKK -12,334 (Q4 2023: kDKK -6,413).

• FY 2024 gross loss: kDKK -32,731 (FY 2023: kDKK -26,169); operating loss: kDKK -40,367 (FY 2023: kDKK -33,214); loss for the period: kDKK -38,211 (FY 2023: kDKK -26,169).

• Total assets at year-end: kDKK 22,314 (2023: kDKK 38,742); equity ratio: 28.4% (2023: 81.0%).

• Earnings per share: DKK -1.81 (2023: DKK -1.32).

• Cash at year-end: kDKK 10,011 (2023: kDKK 20,080); capital increases and warrant exercises contributed to liquidity.

Outlook and guidance

• Plan to enroll first patient in uTREATⓇ brain cancer trial in Q2 2025; CTA submission expected in early Q1 2025.

• Phase II basket trial to launch in 2026, covering five cancer indications using the theranostic platform.

• Ongoing strategic focus on expanding clinical pipeline, accelerating development, and pursuing new partnerships.